The Europe HPV Testing and Pap Test Market would witness market growth of 33% CAGR during the forecast period (2021-2027).
Cervical cancer is majorly preventable. The role of HPV in the growth of cervical cancer enables the installation of prevention techniques for cervical cancer. Primary prevention of cervical cancer is with the help of vaccination against HPV to prevent women from getting infected with oncogenic HPC types that is the major reasons for most of the cervical cancer. Secondary prevention of cervical cancer is with the help of cervical screening to identify and treat abnormalities while they are in the precancerous stage, before the possibility of progression to cervical cancer. This is possible as cervical cancer is one of the cancers having a precancerous stage that lasts for several years before the development of invasive disease, which offers a possibility for detection and treatment. The potential of cervical screening is because of repeating the screening test at decided rescreening periods, which enable highly precise detection of precancerous abnormalities over the long preinvasive stage of squamous cervical cancers.
Identification of precancerous abnormalities via cervical screening utilized cytology from the Papanicolaou smear (PAP test) as the screening tool, with cells gathered from the transformation area of the cervix – the area of the cervix where the squamous cells from the endocervical canal meet. The objective of the screening PAP test is to recognize those women who could have a cervical abnormality and thus, need further diagnostic testing. Therefore, raising awareness about cervical cancer screening programs is likely to accelerate the growth of the market over the forthcoming years.
Cancer of the cervix uteri, more generally termed as cervical cancer, is becoming a major health concern across European countries. In Europe, approximately 58,373 women are diagnosed every year with cervical cancer and 24,404 of them die from this disease. The burden of cervical cancer is specifically high in the new member states. The largest annual mortality rates are currently noted in Romania and Lithuania, and the lowest rates in Finland. Government authorities, parliamentary members, and advocates should be conscious of the fact that the significantly higher dimension of this public health problem in the east of the EU needs special attention.
Over the short and medium term, screening for cervical cancer management and precursors of screen-detected lesions will become one of the highly efficient tools for cervical prevention in Europe. The formulation of in-depth European guidelines regarding the prevention of cervical cancer that properly incorporate screening and vaccination strategies is a major objective of the next phase of guideline development initiatives encouraged by the EU health program.
The Germany market dominated the Europe Vaginal Cancer Screening Market by Country 2020, thereby, achieving a market value of $124.7 million by 2027. The UK market is exhibiting a CAGR of 34.3% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 36% during (2021 - 2027).
Based on Type, the market is segmented into Pap Test and HPV Testing. Based on Application, the market is segmented into Cervical Cancer Screening, and Vaginal Cancer Screening. Based on Product, the market is segmented into Consumables, Instruments, and Services. Based on End Use, the market is segmented into Hospitals & Clinics, Laboratories and Other End Users. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global HPV Testing and Pap Test Market Size will Hit $7.1 Billion by 2027, at a CAGR of 33.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc., and Qiagen N.V.
By Type
By Application
By Product
By End Use
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 